BridgeMD
New treatment option for Long COVID
Official title Taurine Supplementation in Long COVID
ClinicalTrials.gov ID: NCT06721949
What this study is testing
What is Taurine?
Taurine is an investigational medicine, being studied as a potential treatment for long covid.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The COVID-19 pandemic has swept across the globe, affecting millions of individuals with varying degrees of severity. While many individuals recover from the acute phase of the infection, a significant proportion continue to experience persistent and debilitating symptoms long after the initial SARS-CoV-2 infection.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥18 years;
- Positive COVID-19 test by nasopharyngeal swab RT-PCR test, antibody or antigen tests at least 3 months prior to randomization; OR Presumed COVID-19...
- If participants have treatable symptoms, they should have had a stable regimen of treatment prior to entering the study (i.e. started treatment for...
- Lingering COVID-19 symptoms beyond 3 months from onset of acute COVID and symptoms have lasted at least 2 months. The onset of COVID is considered...
- Lingering symptoms from COVID-19 present at the time of randomization.
You likely can't join if
- Patients who had mechanical ventilation or extracorporeal membrane oxygen (ECMO) for COVID-19.
- Current end-organ failure, organ transplantation, or current hospitalization in an acute care hospital.
- Contraindications to the study intervention.
- Currently already on study intervention(s).
- Co-enrolment in another treatment trial (co-enrolment in an observational study is permitted).
- Currently pregnant or breastfeeding.
See the full eligibility criteria
- Age ≥18 years;
- Positive COVID-19 test by nasopharyngeal swab RT-PCR test, antibody or antigen tests at least 3 months prior to randomization; OR Presumed COVID-19 assessed by the site investigator (no positive COVID-19 test) with...
- If participants have treatable symptoms, they should have had a stable regimen of treatment prior to entering the study (i.e. started treatment for at least 4 weeks).
- Lingering COVID-19 symptoms beyond 3 months from onset of acute COVID and symptoms have lasted at least 2 months. The onset of COVID is considered the earliest of two dates: the date of positive testing or the date of...
- Lingering symptoms from COVID-19 present at the time of randomization.
- Individuals of childbearing potential (as assessed by the overseeing Investigator) who are sexually active must agree to practice true abstinence or use at least one highly effective method of contraception while on...
- Must be able to provide informed consent and both willing and able to comply with study requirements.
- Medications prescribed for treating fatigue or cognition have been discontinued for four weeks prior to enrolment and randomization. These include sildenafil, modafinil (Provigil), or armodafinil (Nuvigil), guanfacine...
- Patients who had mechanical ventilation or extracorporeal membrane oxygen (ECMO) for COVID-19.
- Current end-organ failure, organ transplantation, or current hospitalization in an acute care hospital.
- Contraindications to the study intervention.
- Currently already on study intervention(s).
- Co-enrolment in another treatment trial (co-enrolment in an observational study is permitted).
- Currently pregnant or breastfeeding.
- The participant is currently enrolled in another clinical trial to treat neurocognitive symptoms in LC.
The study team makes the final eligibility decision.
Where it's taking place
- Edmonton, Alberta, Canada
- Vancouver, British Columbia, Canada
- Toronto, Ontario, Canada
- Montreal, Quebec, Canada
- Sherbrooke, Quebec, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Edmonton, Alberta, Canada; Vancouver, British Columbia, Canada; Toronto, Ontario, Canada; Montreal, Quebec, Canada; Sherbrooke, Quebec, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.